CD44 and urinary bladder cancer: For instance, Li et al.17used a combination of BCMab1 and CD44 monoclonal antibodies to isolate the BCMab1+/CD44+ subset in bladder cancer, which exhibited enhanced stem cell-like properties, including proliferation and self-renewal.